However, PD1/PD-L1 inhibitors, in combination with chemotherapy, radiotherapy, targeted drug therapy, and other immunotherapies, are capable of increasing CD8+ T cell number in the patient's tumor microenvironment, disrupting tumor immune escape, and enhancing the antitumor effect of PD1/PD-L1 inhibitors [18, 21]. Here, CD274 is linked to neoplasm.